Rocket Lab USA Inc vs Stryker Corporation — how do they compare? Rocket Lab USA Inc trades at $63.08 (market cap $42.12B), while Stryker Corporation trades at $276.5 (market cap $106.03B). The key difference: Stryker Corporation is far larger — about 2.5× Rocket Lab USA Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| RKLB | SYK | |
|---|---|---|
Market Cap | $42.12B | $106.03B |
Sector | Technology | Technology |
52-Week High | $150.23 | $388.79 |
52-Week Low | $39.48 | $275.39 |
Enterprise Value | $39.95B | $117.50B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $65.87, up 2.51% on the day, but remains in a bearish technical trend below key resistance levels. The company reported record Q2 2026 revenue of $234 million, up 62% year-over-year, yet continues to post significant net losses. Recent news highlights progress on the Neutron rocket and the pending Iridium Communications acquisition, but investor sentiment is mixed due to execution risks and delays.
The outlook hinges on successful Neutron deployment and path to profitability. Analysts see substantial upside with a $117.44 consensus target, but risks include cash burn, competitive pressure, and potential further launch delays. The stock offers high-growth potential for risk-tolerant investors betting on the space economy's expansion.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Trailing returns across standard periods
Latest headlines on both assets
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →